Posted inClinical Updates Gastroenterology news
Rifasutenizol-Based Triple Therapy Versus Bismuth Plus Clarithromycin Triple Therapy for First-Line Helicobacter pylori Eradication: Analysis of the EVEREST-HP Phase 3 Trial in China
EVEREST-HP demonstrates that rifasutenizol-based triple therapy offers non-inferior H. pylori eradication with improved tolerability compared to bismuth plus clarithromycin triple therapy in treatment-naive Chinese patients.